Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
Titel:
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
Auteur:
Oriol, Albert Hájek, Roman Spicka, Ivan Sandhu, Irwindeep Cohen, Yael C. Gatt, Moshe E. Mariz, José Cavo, Michele Berdeja, Jesús Jin, Kexin Bar, Merav Das, Prianka Motte-Mohs, Ross La Wang, Yu Perumal, Deepak Costa, Luciano J.